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| I N T R O D U C T I O N
Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) is a familial cancer syndrome associated with the development of cutaneous and uterine leiomyomas and a highly aggressive form of type 2 papillary kidney cancer. [1] [2] [3] [4] Cutaneous and uterine leiomyomas are common clinical features of HLRCC; [5] [6] [7] kidney cancer presents in a minority of HLRCC patients. 6, 7 Notably, HLRCC renal tumors can be aggressive, with patients at risk to develop locally advanced or disseminated disease even when associated with small primary tumors 1-2 cm in size. 3 Due to the propensity for HLRCC-associated kidney cancer to spread when the primary tumors are small, it is important to screen at risk individuals periodically from a relatively young age, and HLRCC-associated kidney cancer has been diagnosed in children as young as 11 years old. 1, 8 Therefore, accurate identification of "at risk" individuals is needed.
HLRCC is an autosomal dominant inherited cancer syndrome characterized by a germline mutation of the fumarate hydratase (FH) gene in chromosome band 1p42.1 that encodes the enzyme responsible for conversion of fumarate to malate in the Krebs cycle. 6, 7, 9 Cells in which there is somatic loss of the remaining wild-type copy of the FH gene undergo a metabolic shift to aerobic glycolysis with impaired oxidative phosphorylation. Loss of FH is associated with increased levels of fumarate. 10, 11 Increased intracellular fumarate can inhibit several a-ketoglutarate dependent dioxygenases including the prolyl hydroxylase domain enzymes leading to increased levels of hypoxia inducible factor (HIF) and activation of the HIF pathway. 10, 12 Additionally, increased intracellular fumarate induces succination of KEAP1, resulting in loss of NRF2 transcription factor inhibition and upregulation of the antioxidant response pathway that can combat the increased levels of reactive oxygen species associated with FH-deficient RCC. 13, 14 In our previous experience, germline FH gene mutation detection was positive in nearly 90% of patients with phenotypic manifestations consistent with HLRCC. 7 The In another autosomal dominant inherited kidney cancer syndrome, von Hippel-Lindau, patients can present with germline mutation, partial deletion, or complete deletion of the VHL disease gene. 20, 21 It has been
shown that the size of the deletion can affect the overall incidence of kidney cancer with the additional loss of the BRK1 (HSPC300) gene significantly lowering the rate of kidney cancer. 22, 23 Within our cohort of kindreds, we have a number of suspected or clinically confirmed HLRCC patients, both with and without kidney cancer, for which no FH point mutation had been identified. This study was conducted to search for complete or partial FH gene deletion in these kindreds and to characterize the phenotypic manifestations of these families and represents the largest case study reported to date. 
| M E T H O D S

| CLIA-Approved FH deletion/duplication analysis
Several commercial companies provide a service for the evaluation of deletions or duplications of the FH gene. All patients from the seven families with germline deletions identified by the Agilent custom highdefinition CGH array were confirmed by CLIA-approved FH deletion/ duplication analysis provided by either GeneDx, the Children's Hospital of Philadelphia (CHOP), or Emory Genetics Laboratory. A further six patients were directly evaluated using CLIA-approved FH deletion/ duplication analysis provided by the same companies.
| Real-time PCR-based deletion analysis
The CLIA deletion analysis report by GeneDx for the patient represent- MA) using standard reverse transcriptase PCR (RT-PCR) conditions. A normal blood control was used to represent normal copy number and the genomic DNA from a member of the UOB-1815 complete FH deletion family was used to represent single copy number loss at these loci.
All reactions were normalized to a primer pair for the ALB gene on chromosome 4 as a control for normal copy number.
| PCR
Primers were designed adjacent to the estimated deleted region boundaries, and a Qiagen Taq PCR Core Kit (Germantown, MD) was used to amplify the deletion boundaries. DNA fragments were gel purified using E-Gel SizeSelect Gels (Life Technologies, Grand
Island, NY).
| Sequencing
All purified DNA products were sequenced bidirectionally using the Big Dye Terminator v.1.1 Cycle Sequencing Kit (Applied Biosystems) according to manufacturer's specifications and run on an ABI 3130xl
Genetic Analyzer.
| R E S U L T S
Our initial family (UOB-1815) with clinical features suggestive of HLRCC and extensive kidney cancer disease was investigated by FISH analysis using a probe that encompassed the first six exons of the FH gene (409K12 (RPC1-11) ). This demonstrated a germline deletion of FH in multiple members of this family including patients with kidney cancer but did not assess the extent of the deletion beyond the extent of the probe ( Figure 1A ,B). This result was confirmed by CLIAapproved FH deletion/duplication analysis that demonstrated complete loss of the FH gene but did not reveal the extent of the deletion or whether or not additional genes were deleted.
To further investigate UOB-1815 and six other potential HLRCC families (UOB-4428, UOB-4366, UOB-3952, UOB-1126, UOB-4087, UOB-4391), a custom high-definition CGH array that had been designed to assess copy number aberrations in several selected kidney cancer associated genes was used. 24 The array contained a high concentration of probes across the entirety of the FH gene and its surrounding DNA sequence with further probes representing the entire genome at a lower density. This array had the capability to detect the ( Figure 2 and Table 1 ). The deletion breakpoints for two families were (Table 1 ). In addition, two families (UOB-4862 and UOB-4838)
were found to have partial FH germline deletions. While UOB-4862 was shown to have a germline deletion of the terminal four exons of FH (exons 7-10), additional gene loss downstream of the FH gene was not assessed (Table 1) . UOB-4838 was found to have a partial germline deletion in a region upstream of the 5 0 untranslated region (UTR) of the FH gene, but the deletion status of exon 1 was not evaluated and exon 2 did not exhibit loss. Thus, the deletion was reported as having "uncertain significance" due to no observation of loss within the coding region. To further evaluate the extent of this deletion a series of PCR probes were designed within the FH gene and upstream (UpStr) of transcription start site, including the predicted deletion region, exon 1, and intron 1 ( Figure 4A ). Real-Time PCR analysis using these probes demonstrated the expected normal copy number in exons 2 and 10 and the loss of exon 1 and three upstream probes, further refining the minimal deletion and confirming loss within the coding region ( Figure   4A ). Using these data, the deletion breakpoints were mapped to the nucleotide level revealing a 4088 bp deletion which encompassed the entirety of exon 1 of the FH gene (Table 1, Figure 4B ). One of the two breakpoints was in an L2 repeat sequence, and the other was not in or near a repeat element.
Clinical data from 28 patients with germline FH deletions from the 13 UOB families were investigated. Uterine leiomyomas were present in 13/13 (100%) female patients from seven different families (Table   2 ). Uterine leiomyomas were observed in patients with both the largest and second smallest complete FH germline deletions. None of female patients had the partial FH germline deletions (Tables 1 and 2 ). Cutaneous leiomyomas were present in 18/20 (90%) of patients from 11 families ( Table 2 ). Both patients who were negative for cutaneous leiomyomas were members of the UOB-1815 family in which other family members were found to have cutaneous leiomyomas. Cutaneous leiomyomas were observed in patients with both the largest and smallest complete FH germline deletions and in the patients with both (Tables 1 and 2 ). Kidney cancer was present in 9 (32%) of 28 patients that were evaluated and was found in 7 different families ( Table 2) (Tables 1 and 2 ).
| DISCUSSION
HLRCC is a relatively rare syndrome with most HLRCC patients demonstrating a point mutation within FH (90%). 7 The remaining suspected HLRCC patients without detectable point mutations represent an appreciable percentage of patients. In this study we case previously reported, this suggests partial deletion is a rarer event. 15 The mapping of deletion breakpoints revealed no evidence for the involvement of Alu repeats, as is observed in deletions of the VHL kidney cancer risk gene. from 76% to 100% and a rate of uterine leiomyomas in female patients also ranging from 76% to 100%. [5] [6] [7] Kidney cancer was found in 9 (32%) of 28 patients and 7 (54%) of 13 families and was associated with both complete and partial FH gene deletions. In the majority of cases (8/9), the kidney cancers were type 2 papillary renal cell carcinoma, which has been associated with HLRCC. The large HLRCC pedigree (UOB-1815) effectively demonstrates that the presence of the same germline FH deletion can result in varying clinical presentation in different members of the same family.
In comparison, only a single previous report identified FH deletion patients with evidence of HLRCC associated type 2 papillary kidney cancer. 19 This could have been due to the small number of reported cases of germline FH deletion in combination with the lower penetrance of kidney cancer in HLRCC. 22, 23 These findings demonstrate that HLRCC associated type 2 papillary kidney cancer can occur in patients with either complete or partial germline FH deletions, ranging from the smallest partial deletion, resulting in only the loss of the first exon of the FH gene (UOB-4838), to the second largest deletion (UOB-4366) that resulted in a larger loss than any previously mapped. 9, 16 The prevalence of kidney cancer in HLRCC patients in reported cohorts has varied greatly from 2% to 43% and this is partially dependent upon whether the selection criteria for patient acquisition was based on the presence of cutaneous leiomyomas or the combination of leiomyomas and kidney cancer. [5] [6] [7] This study is comparable to the studies that acquired patients due to a combination of leiomyomas and kidney cancer that demonstrated a rate of kidney cancer ranging from 16% to 43% in comparison to the 32% reported in this study. 6, 7 These findings demonstrate that deletion analysis of FH should be performed in patients who are suspected to be at risk for HLRCC. The identification of genomic alteration of FH in patients suspected of being affected with HLRCC will be very useful for both confirming the diagnosis and for effectively screening family members. 25 Testing for the presence of all FH alterations is particularly important due to the highly aggressive nature of the HLRCC-associated type 2 papillary kidney cancers and its potential to manifest in patients at a very early age. 1, 8 Thus, the identification of deletions in these patients and families is important for identifying the relevant at risk individuals and, in particular, ensuring that the appropriate screening and surveillance for all related clinical features can be instigated at the earliest time point to provide the optimal clinical management of these individuals.
